Use of CA‐125 response to predict survival parameters of patients with advanced ovarian carcinoma

Ilan‐Gil ‐G Ron*, Moshe Inbar, Ilana Gelernter, Orly Lewysohn, Daniel Ayalon, Janet Dale, Samario Chaitchik

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The prognostic value of serum CA‐125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CAP) or cyclophosphamide, doxorubicin and cisplatinum (CAP). Patients with serum CA‐125 values below the normal value of 35 U/ml after two courses had a significantly longer median survival (p <0.0001) and longer disease‐free survival (p = 0.007) than did those patients whose CA‐125 levels dropped to normal after the third or a later course of chemotherapy. A response in CA‐125 levels after the first two courses of chemotherapy may indicate which patients should continue with the current chemotherapy regimen and which patients should he ol'fered salvage therapy. 1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted

Original languageEnglish
Pages (from-to)658-662
Number of pages5
JournalActa Obstetricia et Gynecologica Scandinavica
Volume73
Issue number8
DOIs
StatePublished - Sep 1994

Keywords

  • CA‐125 serum level
  • advanced ovarian carcinoma
  • chemotherapy

Fingerprint

Dive into the research topics of 'Use of CA‐125 response to predict survival parameters of patients with advanced ovarian carcinoma'. Together they form a unique fingerprint.

Cite this